David Lebowitz
Stock Analyst at Citigroup
(3.28)
# 954
Out of 4,893 analysts
113
Total ratings
50%
Success rate
1.91%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Upgrades: Neutral | $83 → $129 | $128.55 | +0.35% | 6 | Jun 4, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $44.07 | +27.07% | 3 | May 15, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $14 → $10 | $12.13 | -17.56% | 8 | May 9, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $86 → $80 | $36.63 | +118.43% | 2 | May 7, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.36 | +10.29% | 6 | Mar 4, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $45 → $49 | $45.98 | +6.57% | 4 | Feb 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $42.83 | +49.43% | 12 | Feb 20, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $45 | $48.74 | -7.67% | 4 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Buy | $97 → $88 | $68.72 | +28.06% | 5 | Feb 11, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $38 | $30.40 | +25.00% | 1 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $53.46 | +27.20% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $22.46 | +211.67% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $10.40 | +44.23% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $207 | $175.57 | +17.90% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $21.69 | +70.62% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $308.59 | +23.79% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $59.67 | +60.88% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $4.45 | +169.66% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $320.87 | -48.89% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $14.22 | +174.26% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $9.24 | +127.27% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $4.81 | +8,319.96% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $0.80 | +1,640.64% | 2 | Oct 12, 2021 |
Blueprint Medicines
Jun 4, 2025
Upgrades: Neutral
Price Target: $83 → $129
Current: $128.55
Upside: +0.35%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $44.07
Upside: +27.07%
Intellia Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $12.13
Upside: -17.56%
Cytokinetics
May 7, 2025
Maintains: Buy
Price Target: $86 → $80
Current: $36.63
Upside: +118.43%
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.36
Upside: +10.29%
BridgeBio Pharma
Feb 21, 2025
Maintains: Buy
Price Target: $45 → $49
Current: $45.98
Upside: +6.57%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $42.83
Upside: +49.43%
PTC Therapeutics
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $48.74
Upside: -7.67%
Incyte
Feb 11, 2025
Maintains: Buy
Price Target: $97 → $88
Current: $68.72
Upside: +28.06%
Viking Therapeutics
Feb 7, 2025
Initiates: Neutral
Price Target: $38
Current: $30.40
Upside: +25.00%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $53.46
Upside: +27.20%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $22.46
Upside: +211.67%
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $10.40
Upside: +44.23%
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $175.57
Upside: +17.90%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $21.69
Upside: +70.62%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $308.59
Upside: +23.79%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $59.67
Upside: +60.88%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $4.45
Upside: +169.66%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $320.87
Upside: -48.89%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $14.22
Upside: +174.26%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $9.24
Upside: +127.27%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $4.81
Upside: +8,319.96%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $0.80
Upside: +1,640.64%